Panax notoginseng saponins ameliorate impaired arterial vasodilation in SHRSP.Z-Leprfa/lzmDmcr rats with metabolic syndrome

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 4, 2016, Pages 459-467

  Wu, Ting ^a   Sun, Jianning ^a   Kagota, Satomi ^b   Maruyama, Kana ^b   Wakuda, Hirokazu ^b   Shinozuka, Kazumasa ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Metabolic syndrome; Nitric oxide; Panax notoginseng saponins; Vasodilation

Indexed keywords

CYCLIC GMP; GINSENOSIDE RB 1; GUANYLATE CYCLASE; HERBACEOUS AGENT; NITRIC OXIDE SYNTHASE; PANAX NOTOGINSENG SAPONIN; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NITRIC OXIDE; SAPONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MALE; MESENTERIC ARTERY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PANAX NOTOGINSENG; RAT; VASODILATATION; WISTAR KYOTO RAT; ANIMAL; AORTA; BLOOD; BLOOD PRESSURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; BIOMARKERS; BLOOD PRESSURE; CYCLIC GMP; DISEASE MODELS, ANIMAL; MALE; MESENTERIC ARTERIES; METABOLIC SYNDROME X; NITRIC OXIDE; OXIDATIVE STRESS; PANAX NOTOGINSENG; RATS; SAPONINS; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84961206975     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12547     Document Type: Article

References (39)

1. Yang X, Xiong X, Wang H, Wang J. Protective effects of panax notoginseng saponins on cardiovascular diseases: A comprehensive overview of experimental studies. Evid. Based Complement. Altern. Med. 2014; 2014: 204840.
2. Xu X, Li D, Gao H et al. Protective effect of the traditional Chinese medicine xuesaitong on intestinal ischemia-reperfusion injury in rats. Int. J. Clin. Exp. Med. 2015; 8: 1768-79.
3. Yang X, Xiong X, Wang H, Yang G, Wang J. Xuesaitong soft capsule (chinese patent medicine) for the treatment of unstable angina pectoris: A meta-analysis and systematic review. Evid. Based Complement. Altern. Med. 2013; 2013: 948319.
4. Gui Q, Yang Y, Ying S, Zhang M. Xueshuantong improves cerebral blood perfusion in elderly patients with lacunar infarction. Neural Regen. Res. 2013; 8: 792-801.
5. Pan C, Huo Y, An X et al. Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation. Vascul. Pharmacol. 2012; 56: 150-8.
6. Li H, Deng CQ, Chen BY, Zhang SP, Liang Y, Luo XG. Total saponins of Panax notoginseng modulate the expression of caspases and attenuate apoptosis in rats following focal cerebral ischemia-reperfusion. J. Ethnopharmacol. 2009; 121: 412-18.
7. Lin F, Gou X. Panax notoginseng saponins improve the erectile dysfunction in diabetic rats by protecting the endothelial function of the penile corpus cavernosum. Int. J. Impot. Res. 2013; 25: 206-11.
8. Wan JB, Lee SM, Wang JD et al. Panax notoginseng reduces atherosclerotic lesions in ApoE-deficient mice and inhibits TNF-alpha-induced endothelial adhesion molecule expression and monocyte adhesion. J. Agric. Food Chem. 2009; 57: 6692-7.
9. Kwan CY, Kwan TK. Effects of Panax notoginseng saponins on vascular endothelial cells in vitro. Acta Pharmacol. Sin. 2000; 21: 1101-5.
10. 2+ channels in vascular smooth muscle. Acta Pharmacol. Sin. 1994; 15: 392-8.
11. Shaw DI, Hall WL, Williams CM. Metabolic syndrome: What is it and what are the implications? Proc. Nutr. Soc. 2005; 64: 349-57.
12. Venkatapuram S, Shannon RP. Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome. Am. J. Ther. 2006; 13: 64-71.
13. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol. 2010; 314: 1-16.
14. Ueno T, Takagi H, Fukuda N et al. Cardiovascular remodeling and metabolic abnormalities in SHRSP.Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome. Hypertens. Res. 2008; 31: 1021-31.
15. Hiraoka-Yamamoto J, Nara Y, Yasui N, Onobayashi Y, Tsuchikura S, Ikeda K. Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin. Exp. Pharmacol. Physiol. 2004; 31: 107-9.
16. Sugiyama F, Kobayashi N, Ishikawa M, Onoda S, Ishimitsu T. Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats. Clin. Exp. Nephrol. 2013; 17: 515-24.
17. Tada Y, Kagota S, Matsumoto M et al. Characterization of cardiac size and function in SHRSP.Z-Lepr(fa)/IzmDmcr rats, a new animal model of metabolic syndrome. Biol. Pharm. Bull. 2010; 33: 1971-6.
18. Ueno T, Fukuda N, Nagase H et al. Atherogenic dyslipidemia and altered hepatic gene expression in SHRSP.Z-Leprfa/IzmDmcr rats. Int. J. Mol. Med. 2009; 23: 313-20.
19. Yoshitomi H, Guo X, Liu T, Gao M. Guava leaf extracts alleviate fatty liver via expression of adiponectin receptors in SHRSP.Z-Leprfa/Izm rats. Nutr. Metab. (Lond.) 2012; 9: 13.
20. Kagota S, Maruyama K, Tada Y et al. Chronic oxidative-nitrosative stress impairs coronary vasodilation in metabolic syndrome model rats. Microvasc. Res. 2013; 88: 70-8.
21. Kagota S, Maruyama K, Wakuda H et al. Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome. Vascl. Pharmacol. 2014; 63: 46-54.
22. Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome. Can. J. Physiol. Pharmacol. 2011; 89: 355-64.
23. Kagota S, Fukushima K, Umetani K et al. Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome. Clin. Exp. Pharmacol. Physiol. 2010; 37: 1035-43.
24. Strisciuglio T, De Luca S, Capuano E et al. Endothelial dysfunction: Its clinical value and methods of assessment. Curr. Atheroscler. Rep. 2014; 16: 417.
25. Raij L. Nitric oxide in the pathogenesis of cardiac disease. J. Clin. Hypertens. (Greenwich) 2006; 8: 30-9.
26. Kuo TH, Tseng CT, Lin WH et al. Association between vascular access dysfunction and subsequent major adverse cardiovascular events in patients on hemodialysis: A population-based nested case-control study. Medicine 2015; 94: e1032.
27. Wang M, Xu X, Xu H et al. Effect of the total saponins of Aralia elata (Miq) Seem on cardiac contractile function and intracellular calcium cycling regulation. J. Ethnopharmacol. 2014; 155: 240-7.
28. Shen K, Leung SW, Ji L et al. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Biochem. Pharmacol. 2014; 88: 66-74.
29. Wu J-H, Leung GP-H, Kwan Y-W et al. Suppression of diet-induced hypercholesterolaemia by saponins from Panax notoginseng in rats. J. Funct. Foods 2013; 5: 1159-69.
30. Liu Y, Hao F, Zhang H, Cao D, Lu X, Li X. Panax notoginseng saponins promote endothelial progenitor cell mobilization and attenuate atherosclerotic lesions in apolipoprotein E knockout mice. Cell. Physiol. Biochem. 2013; 32: 814-26.
31. Li X, Wang G, Sun J et al. Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional chinese medicine (TCM) in rats. Biol. Pharm. Bull. 2007; 30: 847-51.
32. Zhou L, Xing R, Xie L et al. Development and validation of an UFLC-MS/MS assay for the absolute quantitation of nine notoginsenosides in rat plasma: Application to the pharmacokinetic study of Panax Notoginseng Extract. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2015; 995-996: 46-53.
33. Lin XH, Hong HS, Zou GR, Chen LL. Upregulation of TRPC1/6 may be involved in arterial remodeling in rat. J. Surg. Res. 2015; 195: 334-43.
34. Liu Y, Zhang HG, Jia Y, Li XH. Panax notoginseng saponins attenuate atherogenesis accelerated by zymosan in rabbits. Biol. Pharm. Bull. 2010; 33: 1324-30.
35. Yuan Z, Liao Y, Tian G et al. Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-kappaB translocation. J. Ethnopharmacol. 2011; 138: 150-5.
36. Zeng X-S, Zhou X-S, Luo F-C et al. Comparative analysis of the neuroprotective effects of ginsenosides Rg1 and Rb1 extracted from Panax notoginseng against cerebral ischemia. Can. J. Physiol. Pharmacol. 2014; 92: 102-8.
37. Kubota Y, Umegaki K, Kagota S et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol. Pharm. Bull. 2006; 29: 1756-8.
38. Kagota S, Yamaguchi Y, Tanaka N et al. Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sci. 2006; 78: 1187-96.
39. Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K. Chronic production of peroxynitrite in the vascular wall impairs vasorelaxation function in SHR/NDmcr-cp rats, an animal model of metabolic syndrome. J. Pharmacol. Sci. 2009; 109: 556-64.